CCL2 and triple-A syndrome: We have previously demonstrated that ectopic administration of recombinant MCP-1 to the arterial wall of PKCδ−/− mice, which has an aneurysm-resistant phenotype, was sufficient to restore local inflammatory response and AAA development [15].